CTOs on the Move

Colucid

www.colucid.com

 
CoLucid was founded in 2005 by Pappas Ventures to advance innovative drug candidates with the potential to provide safe and effective treatments for CNS disorders. The company`s investors include Pappas Ventures, Domain Associates, Care Capital, Novo Ventures, Triathalon Medical Ventures, TVM Life Science Management, Auriga Partners and Pearl Street Venture Funds. The company is developing oral lasmiditan for the treatment of migraine headache and intravenous lasmiditan for treatment of headache pain by health care professionals.
  • Number of Employees: 25-100
  • Annual Revenue: $0-1 Million
  • www.colucid.com
  • P.O. Box 425227
    Cambridge, MA USA 02142
  • Phone: 781.365.2596

Executives

Name Title Contact Details

Funding

Colucid raised $55M on 05/07/2015

Similar Companies

IntelGenx

IntelGenx is a leading drug delivery company focused on the development and manufacturing of pharmaceutical films. IntelGenx`s superior film technologies, including VersaFilm®, VetaFilm™ and transdermal, allow for next generation pharmaceutical products that address unmet medical needs. IntelGenx`s innovative product pipeline offer significant benefits to patients and physicians for many therapeutic conditions. IntelGenx`s highly skilled team provides comprehensive pharmaceuticals services to pharmaceutical partners, including R&D, analytical method development, clinical monitoring, IP and regulatory services. IntelGenx`s state-of-the-art manufacturing facility offers full service by providing lab-scale through to pilot- and commercial-scale production.

Allergy Associates Research Center

Allergy Associates Research Center is a Portland, OR-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

200 Pharmacy and Home Medical Supplies

200 Pharmacy and Home Medical Supplies is a Chicago, IL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Karyopharm

Karyopharm Therapeutics Inc. (Nasdaq: KPTI) is an oncology-focused pharmaceutical company dedicated to the discovery, development, and commercialization of novel first-in-class drugs directed against nuclear export and related targets for the treatment of cancer and other major diseases. Karyopharm`s SINE compounds function by binding with and inhibiting the nuclear export protein XPO1 (or CRM1). Karyopharm`s lead compound, XPOVIO™ (selinexor), received accelerated approval from the FDA in July 2019 in combination with dexamethasone as a treatment for patients with heavily pretreated multiple myeloma. A Marketing Authorization Application for selinexor is also currently under review by the European Medicines Agency. In addition to single-agent and combination activity against a variety of human cancers, SINE compounds have also shown biological activity in models of neurodegeneration, inflammation, autoimmune disease, certain viruses and wound-healing. Karyopharm has several investigational programs in clinical or preclinical development.

Tapestry Pharmaceuticals

Tapestry Pharmaceuticals, Inc. is a Boulder, CO-based company in the Healthcare, Pharmaceuticals, and Biotech sector.